Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carolyn V. Kirschner is active.

Publication


Featured researches published by Carolyn V. Kirschner.


International Urogynecology Journal | 2010

Obstetric fistula: the ECWA Evangel VVF Center surgical experience from Jos, Nigeria

Carolyn V. Kirschner; Kathleen J. Yost; Hongyan Du; Jonathan A Karshima; Steven D. Arrowsmith; L. Lewis Wall

Introduction and hypothesisThe objectives of this study are to analyze the surgical outcomes of women undergoing obstetric fistula repair operations at the ECWA Evangel VVF Center, Jos, Nigeria, and to identify factors associated with postoperative urinary continence.MethodsSociodemographic and clinical data were abstracted retrospectively from the Center’s database for patients who underwent vesicovaginal fistula (VVF) repair operations. These data were compared with clinical outcome (“wet” or “dry”) at the time of hospital discharge.ResultsFrom August 1998 to April 2004, 1,084 fistula repair operations were performed on 926 patients. A vaginal approach was used in 90.1% of cases, and postsurgical continence was achieved in 70.5% of patients. Continence was more likely in patients with an intact urethra, an upper or midvaginal fistula, and less fibrosis than in those patients who remained wet.ConclusionsTwo thirds of patients with obstetric fistulas can be cured, with complete restoration of continence and low surgical morbidity, using a transvaginal surgical approach.


Gynecologic Oncology | 2009

The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer

Anna V. Hoekstra; Jean A. Hurteau; Carolyn V. Kirschner; Gustavo C. Rodriguez

OBJECTIVES To evaluate the response rate and toxicity of a regimen comprised of monthly carboplatin and weekly paclitaxel for recurrent ovarian cancer. METHODS We performed a retrospective chart review of patients with recurrent ovarian cancer treated between 2001 and 2006 at a single institution with carboplatin AUC 5 (day 1), and paclitaxel 80 mg/m(2) (days 1, 8, 15) of a 28-day cycle. Primary endpoints were response rate, progression-free survival and overall survival. RESULTS Twenty patients were treated with this regimen from 2001 to 2006. Stage ranged from stages IC to IV. All received intravenous platinum and taxane as their initial therapy. Histologic subtypes included papillary serous (17), carcinosarcoma (1), and clear cell (2). The median number of prior regimens was 1 (range 1-3). The overall response rate was 85.0% (15 complete responses, 2 partial responses). Patients with tumors categorized as platinum sensitive had a response rate of 93.3% (14/15) and those with tumors deemed platinum resistant had a response rate of 60.0% (3/5). The median survival has not yet been reached after a median follow-up of 28 months. Neutropenia was the only grade 3/4 toxicity, occurring in 7 patients (35.0%). Platinum hypersensitivity reactions occurred in 5 patients (25.0%) who all successfully continued treatment using a carboplatin desensitization protocol. CONCLUSIONS A monthly carboplatin and weekly paclitaxel regimen is highly active for women with recurrent platinum-sensitive and platinum-resistant epithelial ovarian cancer. The regimen is well tolerated. This pilot series demonstrates the potential for this regimen as treatment of choice among doublet first salvage regimens for patients with recurrent epithelial ovarian cancer, thus warranting multi-institutional study.


Gynecologic Oncology | 2015

Patterns and utility of routine surveillance in high grade endometrial cancer.

Jessica Hunn; Meaghan Tenney; E. Bishop; Kathleen N. Moore; William Watkin; Carolyn V. Kirschner; Jean A. Hurteau; Gustavo C. Rodriguez; Ernst Lengyel; N.K. Lee; S. Diane Yamada

OBJECTIVE To evaluate surveillance methods and their utility in detecting recurrence of disease in a high grade endometrial cancer population. METHODS We performed a multi-institutional retrospective chart review of women diagnosed with high grade endometrial cancer between the years 2000 and 2011. Surveillance data was abstracted and analyzed. Surveillance method leading to detection of recurrence was identified and compared by stage of disease and site of recurrence. RESULTS Two hundred and fifty-four patients met the criteria for inclusion. Vaginal cytology was performed in the majority of early stage patients, but was utilized less in advanced stage patients. CA-125 and CT imaging were used more frequently in advanced stage patients compared to early stage. Thirty-six percent of patients experienced a recurrence and the majority of initial recurrences (76%) had a distant component. Modalities that detected cancer recurrences were: symptoms (56%), physical exam (18%), surveillance CT (15%), CA-125 (10%), and vaginal cytology (1%). All local recurrences were detected by symptoms or physical exam findings. While the majority of loco-regional and distant recurrences (68%) were detected by symptoms or physical exam, 28% were detected by surveillance CT scan or CA 125. One loco-regional recurrence was identified by vaginal cytology but no recurrences with a distant component detected by this modality. CONCLUSIONS Symptoms and physical examination identify the majority of high grade endometrial cancer recurrences, while vaginal cytology is the least likely surveillance modality to identify a recurrence. The role of CT and CA-125 surveillance outside of a clinical trial needs to be further reviewed.


International Journal of Gynecological Cancer | 2017

Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer

Josephine S. Kim; Kathryn A. Mills; J. Fehniger; C. Liao; Jean A. Hurteau; Carolyn V. Kirschner; N.K. Lee; Gustavo C. Rodriguez; S. Diane Yamada; Elena S. Diaz Moore; Meaghan Tenney

Objective This study aims to determine the rate of postoperative venous thromboembolism (VTE) in endometrial cancer patients undergoing robotic hysterectomy with or without extended pharmacologic VTE prophylaxis. Methods/Materials A retrospective chart review of women undergoing robotic hysterectomy with or without other procedures for endometrial cancer from January 2010 to February 2015 was conducted at 2 institutions. Charts were manually abstracted, and rates of VTE within 30 and 60 days after surgery were determined. Patients were then stratified by those who did and did not receive extended VTE prophylaxis. Results A total of 403 patients were included, of which 367 patients (91%) received extended pharmacologic prophylaxis and 36 patients (9%) did not. Low molecular weight heparin prescriptions ranged from 7 to 30 days. Patients receiving extended prophylaxis (EP) were older (63 ± 11 vs 57 ± 12; P = 0.004), more frequently underwent lymphadenectomy (67% vs 34%; P < 0.001), and had higher-grade tumors compared with patients not receiving EP. Overall 30-day and 60-day VTE rates were 0.7% and 1.2%, respectively. There were no significant differences in 30-day and 60-day VTE rates among patients that did and did not receive EP, although a trend toward lower VTE rates in the EP group was observed (30-day rates 0.5% vs 2.8% respectively, P = 0.25; 60-day rates 0.8% vs 5.6%, P = 0.07). Conclusions In this study, 30-day and 60-day VTE rates after minimally invasive surgery for endometrial cancer were low. Rates were also similar to those of previous reports in this setting in which the majority of patients did not receive extended VTE prophylaxis. Given the consistent finding that postoperative VTE in this population is rare regardless of prophylaxis use and the variability in practice patterns for VTE prophylaxis, the development of best practice guidelines for EP use specific to this setting is warranted.


International Urogynecology Journal | 2018

Pubovesical sling for residual incontinence after successful vesicovaginal fistula closure: a new approach to an old procedure

Sunday J. Lengmang; Steven N. Shephard; Avisek Datta; Svjetlana Lozo; Carolyn V. Kirschner

Introduction and hypothesisFor decades, the pubovesical (PV) sling has been in the armamentarium of the fistula surgeon for treating persistent urinary incontinence after successful fistula closure. We report our early experience with slings, and then also introduce a new “tight” PV sling technique for management of post-fistula urethral leak. Our hypothesis is that performance of tight slings might result in improved continence for women with persistent urinary incontinence after obstetric fistula closure.MethodsData from 120 patients in whom some type of sling procedure had been performed between 1996 and 2012 were extracted and labeled as “early slings.” Beginning in October 2014, more complete data were recorded and a more uniform approach was undertaken in 40 patients. Data were extracted from their charts and recorded as “tight slings.” This information was analyzed using Chi-squared analysis.ResultsTight slings were more successful in patients who had less severe fibrosis and who had a shorter time since initial injury. Thirty percent of women who underwent tight slings had improved continence at follow-up.ConclusionPersistent urinary incontinence despite successful surgical closure of obstetrical fistula remains a difficult problem. Tight slings may be warranted in an attempt to avoid urinary diversion.


International Journal of Gynecology & Obstetrics | 2017

Effect of HIV infection on outcomes after surgical repair of genital fistula

Steven N. Shephard; Sunday J. Lengmang; Stephen A. Anzaku; Oluwatobi V. Mamven; Carolyn V. Kirschner

To compare outcomes following surgical repair of genital fistula among Nigerian women with or without HIV.


American Journal of Obstetrics and Gynecology | 2004

The obstetric vesicovaginal fistula: Characteristics of 899 patients from Jos, Nigeria

L. Lewis Wall; Jonathan A Karshima; Carolyn V. Kirschner; Steven D. Arrowsmith


American Journal of Obstetrics and Gynecology | 1996

Angiogenesis factor in endometrial carcinoma: A new prognostic indicator?

Carolyn V. Kirschner; Jose M. Alanis-Amezcua; Victorino G. Martin; Nic Luna; Eileen Morgan; Jih-Jing Yang; Edgardo Yordan


International Urogynecology Journal | 2017

Bladder stones in vesicovaginal fistula: is concurrent repair an option? Experience with 87 patients

Steven N. Shephard; Sunday J. Lengmang; Carolyn V. Kirschner


International Urogynecology Journal | 2016

Urinary diversion for patients with inoperable obstetric vesicovaginal fistula: the Jos, Nigeria experience.

Carolyn V. Kirschner; Sunday J. Lengmang; Ying Zhou; George Chima; Jonathan A. Karshima; Steven Arrowsmith

Collaboration


Dive into the Carolyn V. Kirschner's collaboration.

Top Co-Authors

Avatar

Gustavo C. Rodriguez

NorthShore University HealthSystem

View shared research outputs
Top Co-Authors

Avatar

Jean A. Hurteau

NorthShore University HealthSystem

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Puglisi

NorthShore University HealthSystem

View shared research outputs
Top Co-Authors

Avatar

E.D. Moore

NorthShore University HealthSystem

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

N.K. Lee

University of Chicago

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

E.S. Diaz

NorthShore University HealthSystem

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge